Regeneron's (REGN) Antibody Cocktail Can Prevent Covid-19 Infection for 8 Months, Phase 3 Data Shows

Merck (MRK) and Ridgeback Announce Additional Purchase of 1.4M Courses of Molnupiravir by the US Government

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the United States government will exercise two of its options to purchase a total of 1.4 million additional courses of molnupiravir, an investigational oral antiviral medicine, if the medicine is granted Emergency Use Authorization (EUA) or approval by the U.S. Food and Drug Administration (FDA), for approximately $1 billion. With these exercised options, the U.S. government has now committed to purchase a total of approximately 3.1 million courses of molnupiravir, for approximately $2.2 billion, between authorization and... More

Merck (MRK) Acquisition of Acceleron Pharma Cleared by Antitrust Authorities in Germany and Austria

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its pending acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN) has been cleared by the competition authorities in Germany and Austria.

As previously announced on October 12, 2021, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Acceleron, for $180 in cash, without interest and less any required tax withholding. The receipt of antitrust clearance from the competition authorities in Germany and Austria satisfies one of the... More

Merck (MRK) ahead of Pfizer (PFE) in EU talks on COVID-19 pills -EU source - Reuters

Merck (NYSE: MRK) ahead of Pfizer (NYSE: PFE) in EU talks on COVID-19 pills -EU source - Reuters

Regeneron Pharma (REGN) PT Raised to $850 at SVB Leerink, Following Earnings

SVB Leerink analyst Geoffrey Porges raised the price target on Regeneron Pharma (NASDAQ: REGN) to $850.00 (from $798.00) while maintaining a Outperform rating.

Regeneron Pharma (REGN) PT Raised to $770 at UBS

UBS raised its price target on Regeneron Pharma (NASDAQ: REGN) to $770.00 (from $763.00) while maintaining a Buy rating.... More

Benchmark Downgrades Regeneron Pharma (REGN) to Hold

Benchmark analyst Aydin Huseynov downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Hold.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $647.63 yesterday.

Regeneron Pharma (REGN ) PT Raised to $617 at Morgan Stanley

Morgan Stanley analyst Matthew Harrison raised the price target on Regeneron Pharma (NASDAQ: REGN ) to $617.00 (from $571.00) while maintaining a Equalweight rating.... More

Regeneron Pharma (REGN) PT Raised to $710 at BMO Capital

BMO Capital analyst Matthew Luchini raised the price target on Regeneron Pharma (NASDAQ: REGN) to $710.00 while maintaining an Outperform rating.

The analyst commented, "Regeneron reported a top- and bottom-line beat largely driven by REGEN-COV, though Eylea and Dupixent also exceeded expectations. Dupixent expansion... More

Regeneron Pharma (REGN) PT Lowered to $680 at Evercore ISI

Evercore ISI analyst Dr. Josh Schimmer lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $680.00 (from $690.00) while maintaining a Outperform rating.... More